Generated by AI
ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems. Its current portfolio centers on ANKTIVA, a lead biologic product used with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company also works on additional biologic platforms, including cytokine fusion proteins, DNA and vaccine vectors, NK-cell therapies, and other immunomodulators for cancer and infectious diseases. ImmunityBio’s products and research programs are aimed at addressing unmet needs in oncology and infectious disease treatment through immune-based approaches. Headquartered in San Diego, California, ImmunityBio operates as a commercial-stage company with a focus on bringing biologic therapies from development into clinical use.
Website3530 John Hopkins Court
San Diego, CA, 92121
United States
The latest articles about IBRX.
Summary of Nov 19's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 16's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about IBRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.